Skip to main content
. 2018 Nov 21;38(47):10168–10179. doi: 10.1523/JNEUROSCI.3411-17.2018

Figure 7.

Figure 7.

IL-2/IL-2Ab enhances CD39/CD73 signaling in expanded Tregs. A–C, C57BL/6 mice were pretreated with IL-2/IL-2Ab or IsoAb intraperitoneally for 3 d before tMCAO. Mice were killed 3 d after tMCAO. Blood, spleen, and lymph nodes (LNs) were collected for flow cytometry analysis. A, Gating strategy for CD39 and CD73 expression on CD4+CD25+Foxp3+ Tregs. B, Representative flow cytometry plots for CD39 (left) and CD73 (right) expression on CD4+CD25+Foxp3+ Tregs in blood, spleen, and LNs. C, D, Percentages of CD39+ cells and CD73+ cells among CD4+CD25+Foxp3+ Tregs (C) and the number of CD39+ Tregs and CD73+ Tregs in 105 lymphocytes (D) in blood, spleen, and LNs were higher in the IL-2/IL-2Ab treatment group than those in the IsoAb treatment group. n = 7/group for blood; n = 6–7/group for spleen; n = 4/group for LNs. *p < 0.05, **p < 0.01, ***p < 0.001 IL-2/IL-2Ab versus IsoAb. E, F, Equal numbers of splenocytes were treated with IsoAb, IL-2, IL-2/IL-2Ab, or without any treatment (Non) for 3 d. Representative histogram plots for CD39 (E) and CD73 (F) expression on CD4+CD25+Foxp3+ Tregs are shown. The numbers of CD39+ Tregs (E) and CD73+ Tregs (F) were quantified. n = 4/group. **p < 0.01, ***p < 0.001 versus IsoAb and nontreated control; ###p < 0.001 versus IL-2.